Rhythm Pharmaceuticals, Inc. (RYTM) Financials

RYTM Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 437.3 million 220.0 million
March 31, 2026 442.3 million 204.7 million
Dec. 31, 2025 480.2 million 210.2 million
Sept. 30, 2025 506.9 million 211.2 million

RYTM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -53.3 million 49.2 million
March 31, 2026 -44.2 million 23.1 million
Dec. 31, 2025 -26.3 million 19.3 million
Sept. 30, 2025 -26.6 million 18.8 million

RYTM Net Income

No data available :(

RYTM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 330.9 million - 3.7 million
March 31, 2026 340.6 million - 3.8 million
Dec. 31, 2025 388.9 million - 4.0 million
Sept. 30, 2025 416.1 million - 4.1 million

RYTM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 68.6 million
March 31, 2026 68.0 million
Dec. 31, 2025 66.9 million
Sept. 30, 2025 64.3 million

RYTM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 43.4 million 67.4 million -
March 31, 2026 - 41.7 million 63.6 million -
Dec. 31, 2025 953000 42.0 million 57.5 million -
Sept. 30, 2025 - 46.0 million 52.4 million -

RYTM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 71.3 million 8.9 million
March 31, 2026 60.1 million 7.2 million
Dec. 31, 2025 57.3 million 4.8 million
Sept. 30, 2025 51.3 million 5.5 million

RYTM Revenue by Segment
Graph available only for paid members. Upgrade to see it.

RYTM

Price: $115.48

52 week price:
74.50
122.20

Earnings Per Share: -3.12 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 483700

Ebitda: -8.2 million

Market Capitalization: 7.9 billion

Links: